Medical News / Reported from ADA: Semaglutide Significantly Reduces Long-Term Diabetes Risk Among Obesity Patients

Once-weekly 2.4 mg semaglutide is associated with an approximate 60% reduced risk of type 2 diabetes in patients with obesity, according to new findings presented at the American Diabetes Association (ADA) 2022 Scientific Sessions this weekend. In new late-breaking data presented by study author W. Timothy Garvey, MD, endocrinologist and Butterworth Professor of Medicine in the department of nutrition science at University of Alabama School of Medicine, a team of US investigators found the GLP-1 agonist provided a substantially decreased risk of type 2 diabetes development among people with obesity, regardless of their baseline glycemic status, when combined with diet and exercise. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

New research into the speed of diagnosis of hypertrophic cardiomyopathy in the United States is providing ... read more
In a recent study, a smartphone app using artificial intelligence (AI) predicted heart failure 3 weeks ... read more
Reducing sodium in diet to 4,000 mg/day significantly lowers blood pressure after 1 week, a new ... read more
On November 12, 2023, Lexicon Pharmaceuticals, Inc. announced a post hoc analysis of clinical data from ... read more